Valence 로고
인기
로그인
Loading data for DFTX — first visit, this takes a few seconds.

관심목록에 추가

n/a

NasdaqGS: DFTX · 실시간 가격 · USD
44.94
-1.24 (-2.69%)
종가 기준: Aug 19, 2026, 6:30 PM

(DFTX) Stock Price, Analysis & Data

-2.69%

데이터 없음

매수호가n/a
시가총액6.04B
매출 (ttm)n/a
순이익 (ttm)n/a
베타n/a
EPS (ttm)-3.43
P/E (ttm)n/a
선행 P/En/a
P/B (ttm)n/a
P/S (ttm)n/a
Earnings Daten/a
매도호가n/a
거래량1,003,890
평균 거래량 (20일)3,028,916
시가47.00
전일 종가46.18
일중 범위44.59 - 47.29
52주 범위8.70 - 49.70
애널리스트Strong Buy
목표주가66 (46.86%)
배당n/a
배당락일n/a

DFTX 소개

A detailed description of the company is not yet available....

[더 보기]
산업 n/a
섹터 n/a
IPO 일자 n/a
직원 수 n/a
상장 거래소 n/a
티커 DFTX
전체 기업 정보

애널리스트 전망

애널리스트 17명의 투자의견을 종합하면 DFTX 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 66로, 최근 주가 대비 46.86% 상승 여력입니다.

주가 전망

어닝 서프라이즈

가 Aug 6, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -1.44 예상치 하회 -0.89, 및 -188.00% 전년 대비 감소.
    news image

    1일 전 · Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Glo...

    news image

    5일 전 · Simply Wall St.

    Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus

    Definium Therapeutics (DFTX) is back in focus after reporting positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. This event has quickly refocused atte...

    news image

    5일 전 · Simply Wall St.

    Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)?

    In August 2026, Definium Therapeutics reported that its Phase 3 Voyage trial of DT120 ODT in generalized anxiety disorder met the primary HAM-A endpoint and all key secondary measures, delivering rapi...

    news image

    5일 전 · Simply Wall St.

    Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT

    Definium Therapeutics (NasdaqGS: DFTX) reported positive topline data from its pivotal Phase 3 Voyage trial of DT120 ODT in adults with generalized anxiety disorder. The study met all primary and key ...

    news image

    5일 전 · MT Newswires

    Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

    Definium Therapeutics' (DFTX) phase 3 data for DT120 in generalized anxiety disorder looked better t

    2 페이지 중 1